OBESITY is increasingly recognised as a central driver of advanced liver disease, with new evidence highlighting both its risks and emerging treatment opportunities. Defined as a chronic condition characterised by excess adiposity, obesity is closely linked to metabolic dysfunction-associated steatotic liver disease (MASLD).
Rising Obesity Burden Reshapes Liver Disease Landscape
The prevalence of obesity has reached epidemic levels, affecting around 23% of adults in Europe. This surge is closely tied to a growing burden of liver disease, particularly MASLD and its more severe inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH). MASLD is now a leading cause of cirrhosis, hepatocellular carcinoma, and reason for liver transplantation.
Importantly, obesity is not only a cause but also adversely affects prognosis in chronic liver disease. Higher body mass index is associated with worse outcomes across multiple liver conditions, with patients facing up to a threefold higher risk of clinical deterioration. This association is observed regardless of liver disease aetiology, with increased BMI recognised as a modifiable risk factor for disease progression.
How Obesity Damages the Liver
The biological link between obesity and liver disease is driven by dysfunctional fat tissue. Chronic inflammation in adipose tissue leads to the release of free fatty acids and inflammatory signals that reach the liver. These processes trigger fat accumulation, cellular injury, and fibrosis, eventually increasing the risk of cirrhosis and cancer. These processes can occur even in individuals with normal weight, highlighting that metabolic health and fat distribution may matter more than total body size.
New Therapies Expand Treatment Options
This review highlights clinical evidence that consistently shows that weight reduction improves liver health. A 5% weight loss can improve metabolic complications, while reductions of 10% or more are associated with meaningful improvements in liver inflammation and fibrosis. However, reaching this threshold is difficult with lifestyle interventions alone; even structured programmes often see weight regain within 1–3 years.
Novel anti-obesity medications, particularly Incretin-based therapies, such as GLP-1 receptor agonists, act on the gut–brain axis to reduce appetite and improve metabolic function. These drugs can achieve weight loss of at least 5–10%, alongside improvements in liver fat and cardiometabolic risk. Clinical studies suggest benefits in resolving MASH and reducing disease progression, although improvements in liver fibrosis may take longer. Long-term adherence is essential to sustain benefits, while bariatric surgery offers the most durable weight loss, with potential improvements lasting up to two decades, albeit with procedural risks in advanced liver disease.
Balancing Promise with Uncertainty
Despite promising advances, evidence for both medications and surgery in patients with advanced liver disease remains limited. Weight regain after stopping therapy underscores the chronic, relapsing nature of obesity. Future strategies are likely to combine pharmacological, surgical, and lifestyle approaches, tailored to patient profiles, reinforcing that managing obesity is a critical component of chronic liver disease care, with potential to slow disease progression and improve survival.
Reference
Caussy C, Francque SM. Management of obesity in advanced chronic liver disease. JHEP Rep. 2026;DOI:10.1016/j.jhepr.2026.101749.
Featured image: Maya Kruchancova on Adobe Stock
